3p92

Human mesotrypsin complexed with bovine pancreatic trypsin inhibitor variant (BPTI-K15R/R17G)

spinqualitylabelsall models 3p92, resolution 1.60Å Show:Asymmetric Unit Biological Assembly Drag the structure with the mouse to rotate   Export Animated Image   Print3D Structural highlights 3p92 is a 2 chain structure with sequence from Bovin and Human. Full crystallographic information is available from OCA. For a guided tour on the structure components use FirstGlance. Ligands: CA Related: 2r9p Gene: PRSS3 (HUMAN) Activity: Trypsin, with EC number 3.4.21.4 Resources: FirstGlance, OCA, RCSB, PDBsum Function [BPT1_BOVIN] Inhibits trypsin, kallikrein, chymotrypsin, and plasmin. Publication Abstract from PubMed PRSS3/mesotrypsin is an atypical isoform of trypsin, the upregulation of which has been implicated in promoting tumor progression. Mesotrypsin inhibitors could potentially provide valuable research tools and novel therapeutics, but small molecule trypsin inhibitors have low affinity and little selectivity, while protein trypsin inhibitors bind poorly and are rapidly degraded by mesotrypsin. Here, we use mutagenesis of a mesotrypsin substrate, the Kunitz domain of the amyloid precursor protein (APPI), and of a poor mesotrypsin inhibitor, bovine pancreatic trypsin inhibitor (BPTI), to dissect mesotrypsin specificity at the key P2' position. We find that bulky and charged residues strongly disfavor binding, while acidic residues facilitate catalysis. Crystal structures of mesotrypsin complexes with BPTI variants provide structural insights into mesotrypsin specificity and inhibition. Through optimization of the P1 and P2' residues of BPTI, we generate a stable, high affinity mesotrypsin inhibitor with an equilibrium binding constant Ki of 5.9 nM, a <2000-fold improvement in affinity over native BPTI. Using this engineered inhibitor, we demonstrate the efficacy of pharmacologic inhibition of mesotrypsin in assays of breast cancer cell malignant growth and pancreatic cancer cell invasion. While further improvements in inhibitor selectivity will be important before clinical potential can be realized, our studies support the feasibility of engineering protein protease inhibitors of mesotrypsin and highlight their therapeutic potential. The P2' residue is a key determinant of mesotrypsin specificity: Engineering a high affinity inhibitor with anticancer activity.,Salameh MA, Soares AS, Hockla A, Radisky DC, Radisky ES Biochem J. 2011 Aug 2. PMID:21806544 From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. See Also Basic Pancreatic Trypsin Inhibitor

Proteopedia Page Contributors and Editors (what is this?)

OCA